In light of the previously reported negative correlation between the levels of these cytokines and the duration and severity of ALS [58], this effect of ADRC which inhibits TNF-alpha and IL-1β expression seems to be therapeutically promising. The gene discussed is IL1B; the disease is amyotrophic lateral sclerosis.